Skip Navigation


JAC Advance Access originally published online on July 14, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/2/299    most recent
dkh355v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Budge, P. J.
Right arrow Articles by Graham, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Budge, P. J.
Right arrow Articles by Graham, B. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy 2004 54(2):299-302; doi:10.1093/jac/dkh355
JAC vol.54 no.2 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.

Leading article

Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses

Philip J. Budge1,2,* and Barney S. Graham2,{dagger}

1 Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232; 2 Viral Pathogenesis Laboratory, Vaccine Research Center-NIAID, National Institutes of Health, MSC 3017, Bldg. 40 Room 2502, 40 Convent Dr., Bethesda, MD, 20892–3017, USA

{dagger} Corresponding author. Tel: +1-301-594-8468; Fax: +1-301-480-2771; Email: bgraham{at}nih.gov

The respiratory syncytial virus (RSV) fusion glycoprotein (F) can interact with the small intracellular GTPase RhoA, and peptides derived from RhoA inhibit RSV replication. These observations initially suggested that RhoA-derived peptides might inhibit RSV replication by disrupting an in vivo interaction between RSV F and RhoA. However, recent data indicate that the antiviral activity of RhoA-derived peptides is not due to competitive inhibition of an hypothesized F–RhoA interaction, but is rather a function of the peptides' intrinsic biophysical properties. We summarize here what is known about the mechanism of RSV inhibition by these peptides and give our opinion regarding the potential implications of this work with regards to RSV biology, and to the development of antiviral agents targeting RSV and other enveloped viruses.

Keywords: RSV , polyanions , fusion inhibition , dextran sulphate , sulphated polysaccharides , antiviral agents , post-attachment neutralization , human immunodeficiency virus , HIV , heparin , heparan sulphate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.